Sun Pharma presents follow-up data from ILUMYA Phase 3 reSURFACE 1 and 2 trials EP News Bureau Oct 10, 2019 Additional data show people with and without metabolic syndrome respond similarly to ILUMYA treatment with comparable, positive…
